Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market

Key Takeaways TMO posted Q2 EPS of $5.36 and revenues of $10.85B, both beating the Zacks Consensus Estimate. TMO's Life Sciences and Biopharma Services drove growth, offsetting Analytical Instruments weakness. New product launches like Orbitrap systems and DynaDrive bioreactors boosted TMO's commercial performance.Thermo Fisher Scientific Inc.'s (TMO) second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. ...